• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重视阿片类药物治疗的副作用:患者和医生的权衡分析。

Importance of side effects in opioid treatment: a trade-off analysis with patients and physicians.

机构信息

Simon-Kucher & Partners, Cambridge, Massachusetts 02141, USA.

出版信息

J Pain. 2010 Nov;11(11):1095-108. doi: 10.1016/j.jpain.2010.02.007. Epub 2010 May 10.

DOI:10.1016/j.jpain.2010.02.007
PMID:20452835
Abstract

UNLABELLED

This study examined the relative impact of pain relief and opioid side effects on patients' and physicians' preferences for medication. An Internet survey was completed by 618 patients (302 acute pain, 316 chronic pain) and 325 physicians (83 primary care, 80 pain specialists, 41 oncologists, 40 general surgeons, 40 orthopedic surgeons, 20 rheumatologists, 21 neurologists). Respondents completed an Adaptive Conjoint Analysis (ACA) exercise in which they indicated their relative preference for 20 pairs of hypothetical opioid pain medications described by varying levels of pain relief and side-effect incidence. Almost all patients (96% of chronic, 92% of acute) reported experiencing at least 1 side effect while on opioid medication, but physician-estimated incidence rates of most opioid side effects were much lower than those reported by patients. Opioid side effects, rather than pain relief, explained the majority of variance for medication preference for both patients (74% for chronic, 73% for acute) and treating physicians (73% for chronic, 74% for acute) in this exercise. Nausea and vomiting were major determinants of opioid medication preference, with each explaining as much of the variance in preference as did pain relief (21% to 25%). Nausea and vomiting were the most important side effects based on the amount of pain relief that respondents were willing to give up for reducing the incidence of side effects. The importance of side effects was confirmed in an open-ended question where 51% of patients and 58% of physicians identified side-effect reduction as an unmet need for pain medications.

PERSPECTIVE

This study provided insights into patient and physician preferences of the risk and benefit balance of opioid therapy. This information could improve understanding of patient needs and facilitate the incorporation of patient preference into therapy choice.

摘要

目的

本研究考察了疼痛缓解和阿片类药物副作用对患者和医生对药物选择的偏好的相对影响。通过互联网调查,共完成了 618 名患者(302 名急性疼痛患者,316 名慢性疼痛患者)和 325 名医生(83 名初级保健医生,80 名疼痛专家,41 名肿瘤学家,40 名普通外科医生,40 名骨科医生,20 名风湿病学家,21 名神经科医生)的调查。受访者完成了一项自适应联合分析(ACA)练习,在该练习中,他们根据疼痛缓解和副作用发生率的不同水平,对 20 对假设的阿片类药物疼痛药物的相对偏好进行了评估。几乎所有患者(慢性疼痛患者的 96%,急性疼痛患者的 92%)在服用阿片类药物时至少报告了 1 种副作用,但医生估计大多数阿片类药物副作用的发生率远低于患者报告的发生率。在这项研究中,阿片类药物副作用而不是疼痛缓解解释了患者(慢性疼痛患者的 74%,急性疼痛患者的 73%)和治疗医生(慢性疼痛患者的 73%,急性疼痛患者的 74%)对药物选择的大部分偏好差异。恶心和呕吐是阿片类药物药物选择的主要决定因素,两者对偏好的解释程度与疼痛缓解相当(21%至 25%)。在愿意为降低副作用发生率而放弃的疼痛缓解程度方面,恶心和呕吐是最重要的副作用。在一项开放性问题中,51%的患者和 58%的医生认为减少副作用是疼痛药物的未满足需求,这证实了副作用的重要性。

角度

本研究提供了对患者和医生对阿片类药物治疗风险和益处平衡的偏好的深入了解。这些信息可以提高对患者需求的认识,并促进将患者的偏好纳入治疗选择。

相似文献

1
Importance of side effects in opioid treatment: a trade-off analysis with patients and physicians.重视阿片类药物治疗的副作用:患者和医生的权衡分析。
J Pain. 2010 Nov;11(11):1095-108. doi: 10.1016/j.jpain.2010.02.007. Epub 2010 May 10.
2
Stated preferences of physicians and chronic pain sufferers in the use of classic strong opioids.医生和慢性疼痛患者对经典强效阿片类药物使用的意愿。
Value Health. 2012 Jan;15(1):106-17. doi: 10.1016/j.jval.2011.07.002. Epub 2011 Sep 16.
3
The impact of pain on quality of life and the unmet needs of pain management: results from pain sufferers and physicians participating in an Internet survey.疼痛对生活质量的影响及疼痛管理未满足的需求:参与网络调查的疼痛患者和医生的调查结果
Am J Ther. 2008 Jul-Aug;15(4):312-20. doi: 10.1097/MJT.0b013e31818164f2.
4
Physician management of moderate-to-severe acute pain: results from the Physicians Partnering Against Pain (P³) study.医生对中重度急性疼痛的管理:来自医生对抗疼痛合作组织(P³)研究的结果。
J Opioid Manag. 2013 Nov-Dec;9(6):401-6. doi: 10.5055/jom.2013.0182.
5
In the eye of the beholder: preferences of patients, family physicians, and surgeons for lumbar spinal surgery.在观察者眼中:患者、家庭医生和外科医生对腰椎脊柱手术的偏好。
Spine (Phila Pa 1976). 2010 Jan 1;35(1):108-15. doi: 10.1097/BRS.0b013e3181b77f2d.
6
Danish pain specialists' rationales behind the choice of fentanyl transdermal patches and oral transmucosal systems--a delphi study.丹麦疼痛专家选择芬太尼透皮贴剂和口腔黏膜系统的理由——一项德尔菲研究。
Pain Med. 2009 Nov;10(8):1442-51. doi: 10.1111/j.1526-4637.2009.00724.x. Epub 2009 Sep 29.
7
Patient and physician perceptions of treatment of moderate-to-severe chronic pain with oral opioids.患者和医生对口服阿片类药物治疗中重度慢性疼痛的看法。
Curr Med Res Opin. 2010 Jul;26(7):1579-85. doi: 10.1185/03007991003783747.
8
A national survey of American Pediatric Anesthesiologists: patient-controlled analgesia and other intravenous opioid therapies in pediatric acute pain management.一项针对美国儿科麻醉医师的全国性调查:小儿急性疼痛管理中的患者自控镇痛和其他静脉内阿片类药物治疗。
Anesth Analg. 2010 Mar 1;110(3):754-60. doi: 10.1213/ANE.0b013e3181ca749c.
9
Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).阿片类药物与老年人慢性重度疼痛的管理:一个国际专家小组的共识声明,重点关注世界卫生组织第三阶梯临床最常用的六种阿片类药物(丁丙诺啡、芬太尼、氢吗啡酮、美沙酮、吗啡、羟考酮)。
Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.
10
Physicians' stated trade-off preferences for chronic hepatitis B treatment outcomes in Germany, France, Spain, Turkey, and Italy.德国、法国、西班牙、土耳其和意大利医生对慢性乙型肝炎治疗结果的权衡偏好。
Eur J Gastroenterol Hepatol. 2012 Apr;24(4):419-26. doi: 10.1097/MEG.0b013e328350914c.

引用本文的文献

1
Transforming pain medicine: the power of collaboration, entrepreneurship, and innovation.变革疼痛医学:合作、创业与创新的力量。
Pain Med. 2025 May 1;26(5):231-236. doi: 10.1093/pm/pnae130.
2
Do CYP2D6 genotypes affect oxycodone dose, pharmacokinetics, pain, and adverse effects in cancer?细胞色素P450 2D6(CYP2D6)基因分型是否会影响癌症患者的羟考酮剂量、药代动力学、疼痛及不良反应?
Pharmacogenomics. 2024;25(14-15):579-586. doi: 10.1080/14622416.2024.2430161. Epub 2024 Dec 4.
3
Efficacy of azasetron on postoperative chronic pain after pulmonary surgery: a randomized triple-blind controlled trial.
阿扎司琼对肺手术后慢性术后疼痛的疗效:一项随机、三盲、对照试验。
BMC Anesthesiol. 2024 Jul 30;24(1):261. doi: 10.1186/s12871-024-02653-z.
4
Subhypnotic Intravenous Ketamine Improves Patient Satisfaction With Burn Wound Care: A Quality Improvement Project.亚催眠剂量静脉注射氯胺酮可提高烧伤患者对伤口护理的满意度:一项质量改进项目。
J Burn Care Res. 2024 May 6;45(3):771-776. doi: 10.1093/jbcr/irad204.
5
Hepatic Hilar Block as an Adjunct to Transarterial Embolization of Neuroendocrine Tumors: A Retrospective Review of Safety and Efficacy.肝门区阻滞作为神经内分泌肿瘤经动脉栓塞术的辅助手段:安全性和有效性的回顾性研究
Cancers (Basel). 2023 Oct 29;15(21):5202. doi: 10.3390/cancers15215202.
6
Comparison of Different Modeling Approaches for Prescription Opioid Use and Its Association With Adverse Events.不同处方阿片类药物使用建模方法的比较及其与不良事件的关联。
Am J Epidemiol. 2023 Sep 1;192(9):1592-1603. doi: 10.1093/aje/kwad115.
7
Role of primary sensory neurone cannabinoid type-1 receptors in pain and the analgesic effects of the peripherally acting agonist CB-13 in mice.初级感觉神经元大麻素受体 1 在疼痛中的作用和外周作用激动剂 CB-13 在小鼠中的镇痛作用。
Br J Anaesth. 2022 Jan;128(1):159-173. doi: 10.1016/j.bja.2021.10.020. Epub 2021 Nov 26.
8
Perspectives of pain specialists, patients, and family members on long-term opioid use for chronic non-cancer pain: a qualitative study.疼痛专家、患者和家属对慢性非癌性疼痛长期使用阿片类药物的看法:一项定性研究。
BMC Anesthesiol. 2021 Nov 9;21(1):275. doi: 10.1186/s12871-021-01501-8.
9
Evaluating the efficacy of intranasal oxytocin on pain and function among individuals who experience chronic pain: a protocol for a multisite, placebo-controlled, blinded, sequential, within-subjects crossover trial.评估鼻内催产素对慢性疼痛患者疼痛和功能的疗效:一项多中心、安慰剂对照、双盲、序贯、自身对照交叉试验方案。
BMJ Open. 2021 Sep 23;11(9):e055039. doi: 10.1136/bmjopen-2021-055039.
10
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Tolerability, and Safety of Celecoxib Oral Solution (ELYXYB) in Acute Treatment of Episodic Migraine with or without Aura.塞来昔布口服溶液(ELYXYB)用于伴或不伴先兆的发作性偏头痛急性治疗的疗效、耐受性及安全性的多中心、随机、双盲、安慰剂对照研究
J Pain Res. 2021 Aug 19;14:2529-2542. doi: 10.2147/JPR.S322292. eCollection 2021.